Otonomy Inc

-0.03 (-1.43%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)115.52M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.04 Million
Adjusted EPS-$0.19
See more estimates
10-Day MA$2.15
50-Day MA$2.45
200-Day MA$3.88
See more pivots

Otonomy Inc Stock, NASDAQ:OTIC

4796 Executive Drive, 4796 Executive Drive, San Diego, California 92121
United States of America
Phone: +1.619.323.2200
Number of Employees: 56


Otonomy, Inc. operates as a biopharmaceutical company. It engages in the development of therapeutics for neurotology. The firmâ??s product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.